Literature DB >> 1442996

Recurrent squamous carcinoma of the vulva.

A S Tilmans1, G P Sutton, K Y Look, F B Stehman, C E Ehrlich, N B Hornback.   

Abstract

OBJECTIVE: This study reviews experience at Indiana University with recurrent squamous carcinoma of the vulva over an 18-year period from 1971 to 1989. The pattern of recurrence, time interval to recurrence, and efficacy of salvage therapy are evaluated in the context of the primary tumor. STUDY
DESIGN: This is a retrospective study of 40 patients, 21 of whom underwent primary therapy for invasive squamous carcinoma of the vulva at Indiana University.
RESULTS: Vulvar recurrences were observed in 17 patients (43%), the groin was involved in 12 (30%), whereas pelvic and distant recurrences were observed in 2 (5%) and 9 (22.5%) patients, respectively. Salvage surgery and/or radiotherapy were successful in 25 patients (62.5%) alive from 1 to 144 months (median 8 months) from secondary therapy. Survival after retreatment varied significantly by site of recurrence (p = 0.002), tumor grade (p = 0.009), and interval to recurrence (p < 0.001). Best outcomes were in patients with initial stage I or II disease (International Federation of Gynecology and Obstetrics), grade 1 tumors, local failure, and interval to relapse of > 16 months' duration. Two of 12 patients with groin recurrences were salvaged with surgery and radiotherapy.
CONCLUSION: Long-term follow-up of patients with vulvar cancer and careful restaging at the time of recurrence are mandatory. Although local and nodal recurrences may be controlled with surgery and/or radiotherapy, regional recurrences are usually fatal.

Entities:  

Mesh:

Year:  1992        PMID: 1442996     DOI: 10.1016/s0002-9378(11)91722-0

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  2 in total

1.  An evaluation of prognostic factors, oncologic outcomes, and management for primary and recurrent squamous cell carcinoma of the vulva.

Authors:  Jessie Y Li; Christopher K Arkfeld; Joan Tymon-Rosario; Emily Webster; Peter Schwartz; Shari Damast; Gulden Menderes
Journal:  J Gynecol Oncol       Date:  2021-11-30       Impact factor: 4.756

Review 2.  Recurrent vulvar cancer.

Authors:  Emery M Salom; Manuel Penalver
Journal:  Curr Treat Options Oncol       Date:  2002-04
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.